Postoperative recurrence of clinical early-stage non-small cell lung cancers: a comparison between solid and subsolid nodules.


Journal

Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931

Informations de publication

Date de publication:
07 Jun 2019
Historique:
received: 29 01 2019
accepted: 26 05 2019
entrez: 9 6 2019
pubmed: 9 6 2019
medline: 14 8 2019
Statut: epublish

Résumé

For subsolid non-small cell lung cancers (NSCLCs), solid size (SS), which is the maximal diameter of the solid component, correlates more accurately with tumor prognosis than the total size, which is the maximal diameter of the entire tumor, including ground-glass opacity. We reviewed the propriety of the TNM staging based on the SS for early-stage NSCLCs. We retrospectively reviewed the preoperative radiological reports, clinical records, and pathological reports of NSCLC cases in our hospital between 2010 and 2013, and clinical stage (c-Stage) 0 and I tumors were selected. Disease-free survival (DFS), based on survival analysis, was used to assess the tumor characteristics that predicted the prognosis. A total of 247 NSCLC diagnoses in 231 patients (88 women and 143 men; age, 67 ± 7 years) were included in our cohort. They were classified into solid (n = 131) and subsolid (n = 116) nodules. The DFS curves indicated that prognosis was significantly worse in the following order: c-Stage 0, c-Stage IA, and c-Stage IB tumors (p = 0.016). Patients with solid nodules showed a significantly worse prognosis than patients with subsolid nodules (p < 0.001). A multivariate Cox proportional hazards model showed that the significant predictive factors for DFS were c-Stage (hazard ratio, 1.600; p = 0.020) and solid nodules (hazard ratio, 3.077; p = 0.031). For early-stage NSCLCs, the c-Stage based on the SS in subsolid nodules was useful for predicting postoperative DFS. In addition, whether nodules were solid or subsolid was another independent prognostic factor.

Sections du résumé

BACKGROUND BACKGROUND
For subsolid non-small cell lung cancers (NSCLCs), solid size (SS), which is the maximal diameter of the solid component, correlates more accurately with tumor prognosis than the total size, which is the maximal diameter of the entire tumor, including ground-glass opacity. We reviewed the propriety of the TNM staging based on the SS for early-stage NSCLCs.
METHODS METHODS
We retrospectively reviewed the preoperative radiological reports, clinical records, and pathological reports of NSCLC cases in our hospital between 2010 and 2013, and clinical stage (c-Stage) 0 and I tumors were selected. Disease-free survival (DFS), based on survival analysis, was used to assess the tumor characteristics that predicted the prognosis.
RESULTS RESULTS
A total of 247 NSCLC diagnoses in 231 patients (88 women and 143 men; age, 67 ± 7 years) were included in our cohort. They were classified into solid (n = 131) and subsolid (n = 116) nodules. The DFS curves indicated that prognosis was significantly worse in the following order: c-Stage 0, c-Stage IA, and c-Stage IB tumors (p = 0.016). Patients with solid nodules showed a significantly worse prognosis than patients with subsolid nodules (p < 0.001). A multivariate Cox proportional hazards model showed that the significant predictive factors for DFS were c-Stage (hazard ratio, 1.600; p = 0.020) and solid nodules (hazard ratio, 3.077; p = 0.031).
CONCLUSIONS CONCLUSIONS
For early-stage NSCLCs, the c-Stage based on the SS in subsolid nodules was useful for predicting postoperative DFS. In addition, whether nodules were solid or subsolid was another independent prognostic factor.

Identifiants

pubmed: 31174613
doi: 10.1186/s40644-019-0219-3
pii: 10.1186/s40644-019-0219-3
pmc: PMC6555755
doi:

Types de publication

Journal Article

Langues

eng

Pagination

33

Subventions

Organisme : the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)
ID : 15K09919

Références

Eur J Cardiothorac Surg. 2002 Mar;21(3):514-9
pubmed: 11888773
J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92
pubmed: 12167788
Chest. 2004 Sep;126(3):725-32
pubmed: 15364748
Lung Cancer. 2007 Nov;58(2):231-7
pubmed: 17673328
J Thorac Oncol. 2013 Dec;8(12):1551-7
pubmed: 24389437
Eur Respir J. 2014 Aug;44(2):483-94
pubmed: 24925923
J Thorac Oncol. 2015 Jul;10(7):990-1003
pubmed: 26134221
Ann Nucl Med. 2015 Dec;29(10):897-905
pubmed: 26342592
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):989-96
pubmed: 26581137
J Thorac Oncol. 2016 Aug;11(8):1204-1223
pubmed: 27107787
Ann Thorac Surg. 2016 Aug;102(2):407-15
pubmed: 27177840
Ann Thorac Surg. 2017 Jul;104(1):313-320
pubmed: 28433219
J Thorac Oncol. 2017 Sep;12(9):1403-1412
pubmed: 28627462
Clin Lung Cancer. 2018 Jan;19(1):e37-e45
pubmed: 28666761
Ann Thorac Cardiovasc Surg. 2017 Dec 20;23(6):291-297
pubmed: 28966230
Clin Lung Cancer. 2018 May;19(3):e303-e312
pubmed: 29307591
Radiology. 2018 Jun;287(3):1030-1040
pubmed: 29533722
Lung Cancer. 2018 Jul;121:91-96
pubmed: 29858033

Auteurs

Shingo Iwano (S)

Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. iwano45@med.nagoya-u.ac.jp.

Hiroyasu Umakoshi (H)

Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Department of Radiology, Toyohashi Municipal Hospital, Toyohashi, Japan.

Shinichiro Kamiya (S)

Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Kohei Yokoi (K)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Koji Kawaguchi (K)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takayuki Fukui (T)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shinji Naganawa (S)

Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH